



European  
Lead Factory



THE EUROPEAN LEAD FACTORY:  
**LEADING THE WAY**  
to the discovery of new  
medicines

In collaboration with charities and foundations



The European Lead Factory (ELF) is a collaborative public-private partnership that exists to boost drug discovery in all disease areas. It combines the **innovation** of academia, the **agility** of SMEs and the **experience** of large pharmaceuticals.

Previously only open to European researchers eligible for IMI funding, **the ELF is now offering its services to charities, foundations, and other not-for-profits around the world.**

## THE EUROPEAN LEAD FACTORY: **WORKING WITH YOU**

to give your drug discovery programme a major boost

# YOUR AMBITIONS OUR EXPERTISE

An experienced initiative, the ELF has been running since 2013. Different partners contribute with different expertise and assets, and together we operate a not-for-profit drug discovery platform that includes assay development, high throughput and high content screening, as well as hit selection and hit resynthesis.

Screening takes place on sub-set of ELF Compound Library, a high-quality collection of compounds that is only accessible via the ELF. Over the years, the ELF has delivered on many screening programmes and contributed to various accomplishments.

To find out more about the full ELF compound collection,

[take a look at this publication](#)

Want to know more about the success of the ELF?

[View this publication](#)

**YOUR AMBITIONS.** Are you working on a particular target, phenotype, or in a certain disease area, and would like to find compounds that can lead to novel drug starting points? Please contact us so that we can discuss what we can do for you.



**YOUR RESULTS.**  
The results of a screening campaign at the ELF include a miniaturized assay, a detailed screening report, compound samples & synthetic procedures, and a detailed qualified hit list with compound structures and biological data.

**QUALIFIED HIT LIST.**  
The most promising hit compounds (maximum 50) are cherry-picked by our ELF medicinal chemists. The compound structures, together with all experiments performed, data associated with your hits, assay statistics and recommendations for future work, will be given to you in a detailed report.


**ASSAY DEVELOPMENT & SCREENING.**  
Screening assays will be developed, optimised and/or miniaturized by our ELF experts. After that, the screening will take place on our high-quality compound collection.

**HIT SELECTION.**  
Orthogonal and deselection assays are used to confirm engagement and exclude false positives.

**TAILOR-MADE DRUG DISCOVERY PROGRAMME.**  
Based on your needs and the stage of your drug discovery programme, we can work with you to design a tailor-made screening programme that includes assay development, high throughput or high content screening, hit selection, and resynthesis of the most promising hits.

## COLLECTIVE INTELLIGENCE

for creating new medicines



The ELF is well-positioned to be the partner of choice to move your science forward towards new therapies.

## SCREENING OPTIONS FOR CHARITIES & FOUNDATIONS



### BY PARTNERING WITH US, you will:

- Gain access to the ELF assets and infrastructure (high-quality compound library and state-of-the-art screening facilities)
- Contribute to global health and well-being by leveraging business opportunities in Europe and beyond
- Explore uncharted biological territory through the sourcing of new targets, pathways, and phenotypes to address unmet medical needs

### WORK WITH US and...

- Give your drug discovery programme a major boost
- Play a role in creating a more competitive drug discovery landscape that will have a greater impact on society
- Help expand the thriving life sciences and health sector
- Contribute to new scientific breakthroughs



# THE EUROPEAN LEAD FACTORY: 10 YEARS OF SUCCESS



>300 screening programmes executed



3 IND applications filed & 1 in preparation



9 patent applications filed



2 start-ups created



>100 papers published



## Follow in the steps of the Medicines for Malaria Venture (MMV)

*“ELF provides exciting opportunities for the advancement of anti-malarial drug discovery.”*

**Dr James Duffy, Director of Drug Discovery at MMV**

MMV is a not-for-profit product development partnership (PDP) working to reduce the burden of malaria by discovering, developing and delivering new, effective and affordable antimalarial drugs. MMV has been partnering with the European Lead Factory (ELF) since 2018 to run high-throughput screens for novel antimalarials.

The ELF is a hub for making drug discovery happen. It brings together international leaders and provides a safe space for the exchange of knowledge and data. It connects experts with different skill sets, helping to establish a robust research network of public and private partners focused on drug development.



Read more testimonials on our website.

[Click here](#)

# KEY HIGHLIGHTS OF PARTNERING WITH THE ELF

- For charities, foundations, and other not-for-profits only
- Access to our state-of-the-art ELF screening facilities
- Screening of the full ELF compound library
- Triaging of primary hits
- A Qualified Hit List of max. 50 compounds
- Resynthesis and retesting of the most promising hit compounds
- Access rights and exclusivity to exploit the results
- Full control of programme progression
- Opportunity to start partnering discussions with collaborators of the ELF
- Become part of the ELF network of experts in the area of drug discovery
- Translate your ideas into medicine

# GET IN TOUCH

[programme@europeanleadfactory.eu](mailto:programme@europeanleadfactory.eu)  
[www.europeanleadfactory.eu](http://www.europeanleadfactory.eu)



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806948: 'ESCuLab: European Screening Centre; Unique Library for Attractive Biology'. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Medicines for Malaria Venture (MMV).



A large white spotlight beam originates from the top left and shines down onto a group of silhouetted people walking away from the viewer. The background is a solid dark red color.

THE EUROPEAN LEAD FACTORY:

# **BRINGING TOGETHER**

essential drug discovery  
stakeholders

to translate ideas into medicine